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Background: Platelet collagen receptor GPVI likely functions as a dimer rather than a monomer.
Results: Preformed GPVI dimers, but not monomers, in resting platelets bind specific collagen sequences and are essential for
platelet adhesion and activation.
Conclusion: Constitutive GPVI dimers on resting platelets support platelet adhesion to collagen and activation.
Significance: Resting platelets bind collagen through GPVI dimers, allowing immediate initiation of thrombus
formation.
The platelet collagen receptor glycoprotein VI (GPVI) has
been suggested to function as a dimer, with increased affinity
for collagen. Dissociation constants (Kd) obtained by mea-
suring recombinant GPVI binding to collagenous substrates
showed that GPVI dimers bind with high affinity to tandem
GPO (Gly-Pro-Hyp) sequences in collagen, whereas the
markedly lower affinity of the monomer for all substrates
implies that it is not the collagen-binding form of GPVI.
Dimer binding required a high density of immobilized triple-
helical (GPO)10-containing peptide, suggesting that the
dimer binds multiple, discrete peptide helices. Differential
inhibition of dimer binding by dimer-specific antibodies,
m-Fab-F and 204-11 Fab, suggests that m-Fab-F binds at the
collagen-binding site of the dimer, and 204-11 Fab binds to a
discrete site. Flow cytometric quantitation indicated that
GPVI dimers account for29% of total GPVI in resting plate-
lets, whereas activation by either collagen-related peptide or
thrombin increases the number of dimers to 39 and 44%,
respectively. m-Fab-F inhibits both GPVI-dependent static
platelet adhesion to collagen and thrombus formation on col-
lagen under low and high shear, indicating that pre-existing
dimeric GPVI is required for the initial interaction with col-
lagen because affinity of the monomer is too low to support
binding and that interaction through the dimer is essential
for platelet activation. These GPVI dimers in resting circulat-
ing platelets will enable them to bind injury-exposed suben-
dothelial collagen to initiate platelet activation. The GPVI-
specific agonist collagen-related peptide or thrombin further
increases the number of dimers, thereby providing a feedback
mechanism for reinforcing binding to collagen and platelet
activation.
GPVI2 was identified as a platelet collagen receptor by ana-
lyzing platelets fromGPVI-deficient patients (1, 2). GPVI, com-
plexed with the Fc-receptor -chain (FcR) in the platelet
membrane, interacts with subendothelial collagen exposed
upon vessel injury to initiate platelet activation. Collagen bind-
ing to GPVI induces tyrosine phosphorylation of the immuno-
receptor tyrosine-based activation motifs of FcR and binding
of tyrosine kinase Syk, which generates formation of a signalo-
some, including LAT, SLP-76, and phospholipase C2 (PLC2)
(3), leading to a series of downstream pathways that culminate
in platelet activation.
GPVI, an immunoglobulin receptor family protein, contains
two extracellular immunoglobulin-like domains, D1 and D2
(4). A dimeric structure formed by fusing D1D2 to the IgG Fc
domain exhibited high affinity to collagen, although mono-
mericD1D2 itself showed little collagen affinity (5, 6). Thus, the
GPVI dimer was suggested to have a unique conformation that
gives rise to high affinity binding to collagen. The crystal struc-
ture of the GPVI D1D2 domain (7) indicated that two D1D2
domains can form a dimerwith a dimerization interface located
on the D2 domain, providing direct evidence for dimer forma-
tion, albeit in a nonphysiological setting.
Jung et al. (8) developed antibody Fabs that selectively recog-
nize the GPVI dimer and inhibit GPVI dimer binding to colla-
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gen fibers and platelet activation, suggesting a critical role for
dimerization in GPVI regulation. Demonstration of direct
binding of one of the Fabs,m-Fab-F, to intact platelets indicated
that dimers are present in resting platelets, agreeing with pre-
vious cross-linking studies (9).
Central to understanding the function of GPVI is determin-
ing the following: which collagen sequences are recognized by
the dimer; how dimer formation facilitates platelet binding to
collagen; whether resting platelets contain dimers in numbers
sufficient to allow them to engage collagen; and what effect
platelet activation has on dimer number. This study analyzed
the effects of two dimer-specific Fabs,m-Fab-F and 204-11 Fab,
on binding of recombinant GPVI dimer and monomer to col-
lagen and collagen peptides. Dimeric GPVI accounts for29%
of the GPVI on the surface of resting platelets, with the level
significantly increasing upon platelet activation. Our present
studies demonstrate the physiological role of GPVI dimers by
showing that the dimeric form of GPVI is required for both
platelet adhesion to collagen and subsequent activation.
EXPERIMENTAL PROCEDURES
Antibodies—Monoclonal mouse anti-GPVI antibodies against
the extracellular domain of GPVI, 204-11 (10), 1G5 (11), GPVI-
dimer-specific human antibody Fab m-Fab-F (8), and anti-
GPVI scFv antibody 1C3 (12) were described before. The
human anti-GPVI scFv antibody 10B12 was selected from the
Cambridge Antibody Technology (now MedImmune) phage
display libraries as described previously (13). 204-11was cloned
and 204-11 Fab was prepared as a recombinant protein by
Kaketsuken, Kumamoto, Japan. FITC-conjugated F(ab)2 goat
anti-mouse IgG F(ab)2 antibody (FITC anti-mouse F(ab)2)
was from Jackson ImmunoResearch. 1G5 Fab was prepared
with a Fab preparation kit (Pierce). FITC was conjugated to
m-Fab-F by the EasyLink (FITC) antibody conjugation kit
(Abcam).
Recombinant GPVI Dimer and Monomer—Recombinant
extracellular domain of GPVI (GPVIex, comprising D1D2
(amino acids 1–214) and containing both the N- and O-glyco-
sylation sites; 42 kDa) and the same domain fused with the Fc
domain of human IgG (GPVI-Fc2, 150 kDa) was prepared as
before (5). Convulxin was biotin-labeled using sulfo-NHS-LC-
biotin (Pierce).
Collagen and Collagen Peptides—Collagen Toolkit III pep-
tides and model collagen peptides were synthesized and puri-
fied as described previously (14). Pepsin-treated bovine type I
and type III collagens were from Koken (Tokyo, Japan).
Platelet Preparation—This study was approved by the Cam-
bridge Human Biology Research Ethics Committee; informed
consent was obtained from donors as applicable, according to
the Declaration of Helsinki. Blood was drawn from the antecu-
bital vein of healthy volunteers into 0.1 volume of 3.8% sodium
citrate. Washed platelets were prepared as described before
(15).
ELISA to Determine GPVI Dimer and Monomer Binding to
Anti-GPVI Antibodies or Collagen Substrates—Two types of
enzyme-linked immunosorbent assays (ELISA) were per-
formed as follows: binding of GPVI-Fc2 (dimer) or GPVIex
(monomer) to immobilized antibodies or collagenous sub-
strates and binding of antibody to immobilized dimer ormono-
mer. Substrate was immobilized by reacting the wells of a Nunc
Maxisorp 96-well plate with 50 l of dimer, monomer, anti-
body, collagen, or collagen peptide (10 g/ml) in modified
HEPES/Tyrodes buffer (HT: 136 mM NaCl, 2.7 mM KCl, 0.42
mMNaH2PO4, 5.5 mM glucose, and 5mMHEPES, pH 7.4) over-
night at 4 °C. The substrate-bound wells were blocked with 2%
BSA/HT (1 h). After three washes with HT, ligand (dimer or
monomer for antibody- or collagen-peptide-coated wells and
antibody for dimer- or monomer-coated wells) was added to
the wells and incubated for 1 h. Wells were then washed three
times with HT, and one of the following reagents was added
to the wells: horseradish peroxidase (HRP)-conjugated goat
anti-human IgG Fc (Jackson ImmunoResearch); biotinylated
convulxin followed by HRP-extravidin (Sigma); or HRP-conju-
gated F(ab)2 goat anti-mouse IgG F(ab)2 antibody (HRP-anti-
mouse F(ab)2, Jackson ImmunoResearch). After four washes
with HT, 0.005% Tween 20, bound ligand was visualized by
adding 50l of 1-Step TurboTMB-ELISA (Pierce) to eachwell,
and absorbance at 450 nm was determined after 15–30 min. In
some experiments, Nunc Amino ImmobilizerTM plates were
used, and the same ELISA procedures were followed.
To determine antibody inhibition of dimer binding, a fixed
concentration of GPVI dimer (20 g/ml, 133 nM) was preincu-
bated with different antibody concentrations, and then GPVI
binding to immobilized collagen- or collagen-peptide was
determined by ELISA.
Flow Cytometry—To measure GPVI dimer on intact plate-
lets, 10l of platelet solution, either 5-fold diluted whole blood
or washed platelets (5 107 cells/ml), was mixed with 10 l of
HT solution containing FITC-m-Fab-F (200 g/ml) or 204-11
Fab (40g/ml) and incubated for 10min. For 204-11 Fab, FITC
anti-mouse F(ab)2 antibody (50 g/ml, final) was added as the
secondary antibody and incubated for 10 min. In individual
wells of an Eppendorf 96-well (500 l) deep well plate, each
reactionmixture was diluted with 0.15ml of diluent (Biocytex),
and then antibody binding was measured by an Accuri C6 flow
cytometer (BD Biosciences). Platelet binding to appropriate
controls, unlabeled or FITC-labeled human Fab (Jackson
ImmunoResearch) when m-Fab-F was the primary antibody or
mouse Fab (Jackson ImmunoResearch) when 204-11 Fab or
1G5Fabwas the primary antibody,was determined. The appro-
priate isotype control mouse IgGwas used for 204 IgG and 1G5
IgG binding. Total GPVI was measured in the same manner
except 204-11, 1G5, or 1G5 Fab was used instead of anti-GPVI
dimer antibody. The concentration of each primary antibody
was optimized in preliminary experiments by determining the
antibody concentration versus amount of measured single
chain GPVI; a concentration in the plateau region (maximal
number of single chain GPVI) was chosen for each antibody for
use in the experiments. Similarly the concentration of the sec-
ondary antibody was chosen in this manner.
Tomeasure GPVI in activated platelets, CRP (5 g/ml, final)
or bovine thrombin (0.2 unit/ml, final; Sigma) was added to 100
l of 5-fold diluted whole blood containing 5mMEDTA; after 1
min, 10 l of the reaction mixture was mixed with 10 l of the
primary antibody and processed as described above for the rest-
ing platelets. Agonist concentration dependence of dimer
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increase was measured for both CRP and thrombin using
washed platelets (1  108 cells/ml) and FITC-m-Fab-F (100
g/ml).
The time course of dimer formation in CRP- or thrombin-
induced platelets was measured by adding CRP (5 g/ml, final)
or thrombin (0.2 unit/ml, final) to 1 ml of washed platelets
(2.5  108 cells/ml). At various times, 100 l was taken out of
the reaction mixture and immediately added to 100 l of 1%
paraformaldehyde in HT. After 30min, 0.9 ml of HT, 0.2% BSA
was added to each mixture. The mixture was centrifuged (7000
rpm in a microcentrifuge, 2 min), and the obtained pellet was
suspended in 50 l of HT; 10 l was processed for flow cytom-
etry (FITC-m-Fab-F), as described above.
GPVI Quantitation—In resting and agonist-activated plate-
lets, GPVI dimer was quantitated with the dimer-specific anti-
body 204-11 Fab and total single chain GPVI, with 1G5, 1G5
Fab, and 204-11 IgG, using FITC anti-mouse F(ab)2 and the
Platelet Gp Screen (Biocytex, Marseille, France), which
includes beads conjugated with known amounts of mouse IgG
to make a standard curve, from which the number of GPVI can
be determined.
Effect of Dimer-specific Antibodies on Static Platelet Adhesion
to Immobilized Fibrous Collagen—Fibrous type III collagenwas
prepared as described previously (16). The fibrous collagen sus-
pension (50l of 50g/ml per eachwell) was added to thewells
of a 96-well Nunc ImmobilizerTM Amino plate (Thermoscien-
tific) and incubated overnight at 4 °C; the plates were allowed to
come to room temperature before use. Washed platelets were
preincubatedwithm-Fab-F, 204-11 Fab, 10B12, 1C3, or human
Fab (the control) for 10min prior to initiating the platelet adhe-
sion assay,whichwas performed as described previously (17), in
the presence of 1 mM MgCl2 (total adhesion) or 5 mM EDTA
(GPVI-dependent adhesion). The platelets adhering to the
immobilized fibrous collagenwere lysed, and the alkaline phos-
phatase in the lysate was assayed with the chromogenic sub-
strate p-nitrophenyl phosphate, which is hydrolyzed by the
enzyme to p-nitrophenol, detectable by its absorbance at 405
nm.
Effect of Anti-GPVI Dimer Antibodies on Platelet Adhesion to
a Collagen-coated Surface under Flow—Flow adhesion experi-
ments were performed as described previously (18). Glass cov-
erslips were coated with 0.1 mg/ml type III collagen in 10 mM
acetic acid (4 °C, overnight) and then washed with HT. Blood,
anti-coagulated with 40 M D-phenylalanyl-L-propyl-L-argi-
nine chloromethyl ketone and fluorescently labeled with 1 M
3,3-dihexyloxacarbocyanine iodide, was incubated with 200
g/ml m-Fab-F, 200 g/ml control human Fab, or 100 g/ml
204-11 Fab for 10 min and applied to flow adhesion analysis.
Blood was flowed over the collagen-coated glass at the shear
rate of 300 or 1000 s1; after 5 min, Z-stacks of fluorescence
images of adhered platelets were collected and analyzed by
Image J1.35 (National Institutes of Health). The coverslip plane
was defined as the Z-plane with largest platelet area and used to
calculate the surface area coverage. Mean thrombus height was
calculated as thrombus volume divided by the field area (m3/
m2), and ZV50 was calculated as the Z-height at which the
thrombus volume was half-maximal as described previously
(18). Because we had a limited supply of the relatively low affin-
itym-Fab-F, the results were obtained from two different blood
donors, and experiments were performed in duplicate or
triplicate.
RESULTS
Throughout this paper, GPVIex and GPVI-Fc2 will be
referred to as the monomer and dimer, respectively. The pri-
mary sequencers of the collagenmodel peptides and Toolkit III
peptides used in the experiments are shown in Table 1.
Comparison of Dimer and Monomer Affinities for Immobi-
lized Collagenous Substrates—ELISA (Fig. 1A) was used to
assay GPVI dimer and monomer binding to immobilized col-
lagenous substrates (Table 2) to compare their affinities. The
GPVI dimer bound to CRP; collagen I; collagen III; (GPO)2, a
peptide containing GPVI-binding GPOGPO (19); and
(GPO)2(GPP)4(GPO)2, a peptide containing two GPOGPO
motifs (19). The dissociation constants (Kd) (Table 2) of the
dimer are much lower, indicating that it has 60–900 times
higher affinity for the collagenous substrates than the mono-
TABLE 1
Primary sequences of collagenmodel peptides and Toolkit III peptides
The one-letter amino acid abbreviations are as follows: G, glycine; P, proline; O, hydroxyproline; C, cysteine. CRP stands for collagen-related peptide. The peptide
(GPO)2(GPP)4(GPO)2 was previously abbreviated as (GPO)2(GPO)4 in previous reports. (GPO)10 and (GPP)12 do not contain cysteine, so cannot form cross-linked
polymers. Toolkit III (TK III) peptides with binding affinity to GPVI dimer are shown.
Peptide Sequence
CRP GCO–(GPO)10–GCOG-NH2
III-30A GPC–(GPP)5–GAOGARGGAGPOGPEGGKGAAGPOGPO(GPP)5–GPC–NH2
(GPO)2(GPP)4(GPO)2 GCP–GPPGPOGPOGPPGPPGPPGPPGPOGPOGPP–GCPG–NH2
GPP–10 GCP–(GPP)10–GCPG–NH2
(GPO)1 GCP–GPPGPPGPPGPPGPOGPPGPPGPPGPPGPP–GCPG–NH2
(GPO)2 GCP–GPPGPPGPPGPPGPOGPOGPPGPPGPPGPP–GCPG–NH2
(GPO)4 GCP–GPPGPPGPPGPOGPOGPOGPOGPPGPPGPP–GCPG–NH2
(GPO)6 GCP–GPPGPPGPOGPOGPOGPOGPOGPOGPPGPP–GCPG–NH2
(GPO)10 (GPO)10G–NH2
(GPP)12 (GPP)12G–NH2
TK III-1 GPC–(GPP)5–GLAGYOGPAGPOGPOGPOGTSGHOGSO–(GPP)5–GPC–NH2
TK III-4 GPC–(GPP)5–GPSGPAGKDGESGROGROGERGLOGPO–(GPP)5–GPC–NH2
TK III-9 GPC–(GPP)5–GLOGAAGARGNDGARGSDGQOGPOGPO–(GPP)5–GPC–NH2
TK III-22 GPC–(GPP)5–GSDGKOGPOGSQGESGROGPOGPSGPR–(GPP)5–GPC–NH2
TK III-30 GPC–(GPP)5–GAOGLRGGAGPOGPEGGKGAAGPOGPO–(GPP)5–GPC–NH2
TK III-40 GPC–(GPP)5–GAAGFOGARGLOGPOGSNGNOGPOGPS–(GPP)5–GPC–NH2
TK III-49 GPC–(GPP)5–GDRGENGSOGAOGAOGHOGPOGPVGPA–(GPP)5–GPC–NH2
Pre-existing GPVI Dimer as Collagen Receptor
30002 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 287•NUMBER 35•AUGUST 24, 2012
 at A
ustralian N
ational U
niversity on June 17, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
FIGURE 1. Comparison of the binding of GPVI dimer andmonomer to collagens and collagen-mimetic peptides and effect of peptide density on
dimer binding. A, binding of GPVI dimer (closed triangles) and monomer (closed circles), expressed as A450 units, to immobilized collagen and peptides
(structures shown in Table 1) were determined by ELISA. These data are representative of two separate experiments giving similar results, with binding
data obtained for all the collagen substrates in each experiment; each data point represents themean S.E. of triplicate determinations. Kd values were
obtained by nonlinear regression of the data (Table 2). B, effect of density of immobilized (GPO)10 or CRP-XL (cross-linked CRP) on dimer binding. 100%
(GPO)10 designates wells (Nunc Amino Immobilizer ELISA plate) reacted with 50 l of 10 g/ml (GPO)10; dilutions to lower (GPO)10 were made with the
inert peptide (GPP)12, keeping the total peptide concentration the same (i.e. 10 g/ml, in total), and these were also used to coat the wells. Similarly,
undiluted CRP-XL (10 g/ml) or CRP-XL was diluted with (GPP)12 and used to coat the wells. GPVI dimer binding to the immobilized peptides was
determined by ELISA. A high density of (GPO)10 is required to support dimer binding, with affinity rapidly falling off as the peptide is diluted, suggesting
that the dimer binds to more than one molecule of (GPO)10 (left graph). In contrast, this is not observed with CRP-XL, which forms cross-linked polymers
of CRP molecules in which the component CRP molecules may be close enough so that the dimer can bind across several of them (right graph). Where
no error bars are visible, they are equal to or smaller than the size of the symbol.
Pre-existing GPVI Dimer as Collagen Receptor
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mer. GPP-10, a peptide with no GPO triplets, shows little bind-
ing to dimer (data not shown). The following Hill coefficients
(mean S.E.) were calculated for dimer binding: collagen type I
(1.14 0.07, n 10); collagen type III (1.16 0.11, n 12); CRP
(1.07  0.08, n  6); (GPO)2 (1.07  0.21, n  6); and
(GPO)2(GPP)4(GPO)2 (1.50 0.60, n 4). None of the Hill coef-
ficients were significantly different fromunity (p 0.08), suggest-
ing no cooperative binding of the dimer to any of the peptides.
Effect of Peptide Coating Density on Dimer Binding Affinity—
To determine whether the dimer may bind to a single triple-
helical peptide molecule or across several triple helices, we
immobilized (GPO)10, which does not contain cysteine and so
cannot spontaneously form disulfide-linked homopolymers,
diluted to various densities with the inert peptide (GPP)12.
100% (GPO)10 designates wells reacted with 50 l of 10 g/ml
(GPO)10; dilutions to lower (GPO)10 were made with (GPP)12,
keeping the total peptide concentration the same (i.e. 10 g/ml
in total), and these were also reacted with the wells. Similarly,
CRP-XL (a chemically cross-linked, polymeric form of CRP, 10
g/ml, 100%) was diluted with (GPP)12 and reacted with the
wells. By using the Nunc Amino Immobilizer plates, each pep-
tidemolecule can be separately immobilized via a covalent link-
age to an electrophilic group attached to the plate through a
spacer group. As shown in Fig. 1B, a high density of (GPO)10
was required for dimer binding, with as low as a 1:5 dilution
markedly increasing the Kd value and further dilution reducing
the binding to the level of (GPP)12. This suggests that, presum-
ably, two copies of the (GPO)10 triple helix must be close
enough to allow the dimer to bind to both of them. However,
CRP-XL showed no marked increase in Kd values until it was
diluted to 0.1% because cross-linking multiple individual heli-
ces secures them close enough together to enable a dimer to
bind across two or more of them.
Effect of Number of GPOs on Dimer Affinity to Peptides—The
optimal number of GPO triplets for dimer recognition was
determined bymeasuring binding to peptides containing one to
six GPO triplets (Fig. 2A, ELISA): (GPO)1, (GPO)2, (GPO)4, and
(GPO)6, respectively (19). Dimer bound to (GPO)1most weakly
(Kd 200 nM). The plot of Kd values versus number of GPO
triplets (Fig. 2B) shows that affinity increases about 6-foldwhen
a peptide contains two or more contiguous GPO triplets, indi-
cating that at least two contiguousGPO triplets are required for
good affinity to GPVI dimer.
Dimer Binding toCollagenToolkit III Peptides—Wescreened
the dimer-binding capacity (Fig. 3) of collagen Toolkit III: 57
overlapping homotrimeric peptides comprising the entire pri-
mary sequence of the human collagen III COL domain (14).
The eight peptides with the highest dimer binding were as fol-
lows: high affinity (Kd 3.2 0.3 nM), III-30; moderate affinity
(Kd 14–48nM), III-1, -4, -22, -40, and -49; and low affinity (Kd
90 nM), III-9 and -39 (Fig. 3, inset, peptides listed in decreas-
ing order of affinity).
GPVI Dimer and Monomer Specificity of Anti-GPVI
Antibodies—Dimer and monomer binding to immobilized
antibody (m-Fab-F, 204-11, 204-11 Fab, 1C3, and 1G5, antibod-
ies against the extracellular domain of GPVI) was determined
by ELISA (Fig. 4, A and B). Kd is shown in Table 3.
FIGURE 2. Effect of thenumber ofGPO triplets onGPVI dimerbinding. ELISAwas used to determine dimer binding (expressed asA450 units) to immobilized
collagen mimetic peptides with 1, 2, 4, and 6 GPO triplets, corresponding to peptides (GPO)1, (GPO)2, (GPO)4, and (GPO)6, respectively (Table 1). The data
presented are representative of three experiments giving similar and consistent results; in each experiment, binding curves for the peptides were determined
on the same day and each point is the mean S.E. of triplicate determinations. Data were fitted by nonlinear regression to obtain the Kd values. A, binding
curves;B, graphofKd (calculated from thebinding curves) versus thenumber ofGPO triplets in thepeptides. Peptideswith twoormore contiguousGPO triplets
show about 6-fold higher affinity than (GPO)1 that has only a single GPO triplet, suggesting that GPOGPO is the structure that the dimer binds to with high
affinity.
TABLE 2
Dissociation constants (Kd) for GPVI dimer and monomer binding to
collagenous substrates
Kd
(dimer)
Kd
(monomer)
Kd (monomer)
/Kd (dimer)
nM M
CRP 22.0 2.1 2.7 0.3 122.7
Collagen type I 41.7 0.4 8.1 1.2 194.3
Collagen type III 58.3 9.4 13.8 2.5 236.7
III-30A 11.5 0.6 10.2 1.9 887.0
(GPO)2 75.5 13.8 a
(GPO)2(GPP)4(GPO)2 63.3 17.3 3.8 1.5 60.0
a Binding is too low to establish a Kd value. Kd values were calculated from mea-
surements of dimer binding to each immobilized collagenous substrate by
ELISA (data shown in Fig. 1). CRP indicates collagen-related peptide. The amino
acid sequences of the peptides are shown in Table 2.
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m-Fab-F, designed to bind dimer without binding to either
monomer or the Fc of human IgG, bound to dimer only, as
reported previously (8). Mouse monoclonal antibody 204-11,
raised against the monomer, bound to both dimer and mono-
mer, but it had 25.6-fold higher affinity for the dimer, as shown
by the ratio Kd, monomer/Kd, dimer (Table 3). Unexpectedly,
FIGURE 3. Screening for collagen Toolkit III peptides that bind GPVI dimer. The total set of 57 collagen Toolkit III peptides was screened for their ability to
bind GPVI dimer. Wells were coated with 10 g/ml of Toolkit III peptide, collagen type I, collagen type III, GPP-10, or CRP in 10 mM acetic acid, and binding of
GPVI dimer (20g/ml) to the immobilized substratewasmeasured by ELISA usingHRP-labeled anti-human Fc2 antibody. Binding is expressed as A450, and the
data are normalized to the binding of dimer to collagen type III. Each bar shows the mean  S.E. of three experiments, triplicate determinations for each
immobilized substrate. The dimer binding affinities (Kd values) of peptides with the highest affinities for dimer are shown in the inset, in order of decreasing
affinities (ND  not determined). The inset also shows the IC50 values for inhibition of dimer binding by the dimer-specific antibody m-Fab-F; in these
experiments, dimer was preincubated with different concentrations of m-Fab-F and then reacted with immobilized peptide, using the ELISA method as
described under “Experimental Procedures.”
FIGURE 4. Antibody binding curves for GPVI dimer and monomer. A, binding of GPVI dimer to immobilized antibody: m-Fab-F (black closed diamonds),
204-11 Fab (black closed triangles), 204-11 IgG (gray inverted closed triangles), 1G5 (gray closed circles), and 1C3 (gray closed squares) determined by ELISA using
HRP-labeled anti-human-Fc antibody. B, binding of GPVI monomer to immobilized antibody determined by ELISA using biotinylated convulxin/HRP-labeled
extravidin; symbols are the same as those for A. C, binding of 204-11 Fab to immobilized GPVI dimer (closed circles) and monomer (closed triangles), as
determined by ELISA using HRP-labeled anti-mouse Fab. Binding of GPVI or antibody was expressed as the absorbance at 450 nm. The data presented are
representativeof three (A), two (B), and two (C) experimentsgiving similar andconsistent results; eachpoint is themeanS.E. of triplicatedeterminations.Data
were fitted by nonlinear regression to obtain the binding parameters (Table 3). Where no error bars are visible, they are equal to or smaller than the size of the
symbol.
TABLE 3
Dissociation constants for binding of GPVI dimer andmonomer to antibodies against the extracellular domain of GPVI
Antibody Form
GPVI dimer GPVI monomer
Kd (monomer)/Kd (dimer) SpecificityKd (dimer) Bmax, A450/well Kd(monomer) Bmax, A450/well
nM nM
m-Fab-F Fab 10.83 0.60 0.41 0.01 a a Dimer
204-11 Fab Fab 1.05 0.10 0.57 0.01 a a Dimer
204-11 IgG 0.16 0.01 0.65 0.01 4.09 0.44 0.54 0.01 25.6 Both
1G5 IgG 0.37 0.03 0.61 0.01 0.20 0.02 0.64 0.01 0.5 Both
1C3 scFv 0.59 0.08 0.43 0.01 20.53 2.63 3.88 0.01 34.8 Both
a Because of low (204-11 Fab) or no (m-Fab-F) binding of the antibody, kinetic parameters of acceptable accuracy could not be calculated. The Kd and Bmax values for 204-11
(IgG), 1G5, and 1C3 were calculated from the data shown in Fig. 4 (dimer binding to immobilized antibodies determined by ELISA). To facilitate the comparison of Bmax
values, these data were obtained at one time and show the results of one experiment, which is representative of three experiments showing consistent results.
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204-11 Fab was found to bind dimer only for all practical pur-
poses, with monomer binding being too low to establish accu-
rate kinetic constants (Fig. 4B). In the reverse ELISA, binding of
204-11 Fab to immobilized GPVI monomer (Fig. 4C), the Fab
bound no monomer. The difference between the two ELISAs
may be due tomonomers being less stable to immobilization or
different exposure of binding surfaces.
Although1C3,anantibodyagainst recombinantGPVImono-
mer D1D2 (13), binds both dimer and monomer, its Kd value
indicates that it is dimer-selective. Interestingly, 1G5, an anti-
body raised against recombinant GPVI monomer GPVIex, had
higher affinity for the monomer than the dimer, but the differ-
ence in affinity was insufficient to make it monomer-specific.
Inhibition of Dimer Binding to Collagenous Substrates by
Anti-GPVI Antibodies—The epitopes of our GPVI dimer-spe-
cific antibodies (m-Fab-F and 204-11 Fab) and those of antibod-
ies binding both forms (1C3 and 1G5) were analyzed by deter-
mining their effect on dimer binding to the collagenous
substrates (Fig. 5). 1G5 did not inhibit dimer binding to any of
the substrates (data not shown). m-Fab-F at concentrations
commensurate with its binding affinity nearly completely
inhibited dimer binding to immobilized collagens I and III,
(GPO)2, (GPO)2(GPP)4(GPO)2, andToolkit peptides III-39 and
III-40, whereas it decreased dimer binding to each of the high
affinity substrates, Toolkit peptide III-30 and CRP, by 40%.
1C3 almost completely inhibited dimer binding to all sub-
strates, including CRP. 204-11 Fab exerted various degrees of
partial inhibition against the collagenous substrates.
We determined the relationship between dimer binding
affinity and the ability of m-Fab-F to inhibit dimer binding to
immobilized Toolkit III peptides by calculating its IC50 value in
ELISAs in which a fixed amount of dimer was preincubated
with different concentrations ofm-Fab-F and then reactedwith
an immobilized Toolkit III peptide. The calculated IC50 values
for m-Fab-F were inversely related to the Kd value of dimer
binding to the peptide (Kd values and IC50 for m-Fab-F shown
in Fig. 3, inset).
Relative Amounts of GPVI Dimer in Resting and Agonist-ac-
tivated Platelets—Flow cytometry was used tomeasure relative
amounts of GPVI dimer in resting and activated platelets by
direct binding of FITC-m-Fab-F to platelets in whole blood or
washed platelets in the presence of 5 mM EDTA. In all samples
analyzed using whole blood (n 16), the median fluorescence
intensity of m-Fab-F binding to resting platelets was more than
that of FITC-labeled control Fab to resting platelets (6523 
859 versus 2001 277, p 0.0002). In Fig. 6A, the panel shows
FIGURE 5. Effect of anti-GPVI antibodies on binding of GPVI dimer to collagen, collagen peptides, and representative collagen Toolkit III peptides.
ELISA was used to measure GPVI dimer binding to immobilized collagen I and III, CRP, (GPO)2, (GPO)2(GPP)4(GPO)2, and three representative collagen Toolkit
III peptides: III-30 (high affinity), III-40 (moderate affinity), and III-39 (lowaffinity). A fixed concentrationofGPVI dimer (20g/ml)was preincubatedwith various
concentrations of an antibody before binding to immobilized peptide. Antibodies used were as follows: GPVI dimer-specific antibodies: m-Fab-F (black open
circles) and 204-11 Fab (gray closed diamonds); and an antibody binding to both GPVI dimer andmonomer, 1C3 (black closed squares). Each point on the curve
represents the mean S.E. of triplicate determinations. Where no error bars are visible, they are equal to or smaller than the size of the symbol.
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median fluorescence intensity, and the right panel shows a plot
of fluorescence intensity distribution. m-Fab-F binds more to
platelets activated by 5 g/ml CRP (8613 826, p 0.0001) or
0.2 unit/ml thrombin (10454 921, p 0.0001) than to resting
platelets, with thrombin inducing a greater increase in median
fluorescence intensity than CRP (p 0.0035).
Similar results were obtained detecting m-Fab-F binding to
platelets in whole blood using a FITC-anti-His secondary anti-
body; resting platelets bindmorem-Fab-F (4554 612, n 11,
p 0.003) than control Fab (2675 366), andCRP- and throm-
bin-activated platelets bind more m-Fab-F than resting plate-
lets (5673  877, p  0.0129, and 5882  935, p  0.0207,
respectively, n 11).
Time and Concentration Dependence of Dimer Increase
Induced by CRP and Thrombin—Dimer levels started to
increase after 30 s of treatment with either CRP or thrombin,
reaching a maximum at 4–5 min (Fig. 6B). Both CRP (Fig. 6C,
top panel) and thrombin (Fig. 6C, bottom panel) caused a con-
centration-dependent increase in dimer level, reaching a max-
imum at0.5 g/ml and0.5 unit/ml, respectively.
Quantitation of GPVI Dimers by Flow Cytometry (Fig. 7 and
Table 4)—All determinations were donewith platelets in whole
blood in the presence of EDTA to prevent activation, and anti-
bodies of mouse origin were used.
The total number of single-chain GPVImolecules was calcu-
lated from the measured values (Fig. 7) by the following
method. Quantitation of total GPVI using either 204-11, 1G5,
or 1G5 Fab as the primary antibody gave a similar number of
antibody-binding sites, indicating that each Fab of the FITC
anti-mouse F(ab)2 binds one Fab of the anti-GPVI antibody,
whether the latter is intact IgG or Fab (Fig. 7C, panel i). ELISA
(Fig. 7A) also shows that 1G5 IgG (Bmax  0.799  0.015 A450
units/well) and Fab (Bmax  0.797  0.007 A450 units/well)
bound to immobilized dimer to the same extent. These results
FIGURE 6. Flow cytometry to determine relative amounts of GPVI dimer on intact resting and activated platelets. A, dimer determination by direct
binding of FITC-labeledm-Fab-F to resting, CRP-activated, and thrombin-activated platelets; FITC-labeled control human Fabwas used as the control. The left
panel compares the median fluorescence intensity, and each bar represents the mean S.E. (n 16), using platelets from different donors; the right panel
shows the data from one representative determination. There is a significant increase (p 0.0002) in median fluorescence intensity (MFI) in resting platelets,
comparedwith resting platelets incubatedwith the control Fab, demonstrating the existence of dimers. There is an increase in dimer in platelets activated by
5 g/ml CRP (p 0.0001) or 0.2 unit/ml thrombin (p 0.0001), with thrombin inducing a greater increase than CRP (p 0.0035). **, p 0.001–0.01; ***, p
0.001. B, time course of dimer formation in platelets induced by CRP (closed circles) or thrombin (open squares). Washed platelets (2.5 108 cells/ml, 1ml) were
addedwith CRP (5g/ml, final concentration) or thrombin (0.2 unit/ml, final concentration); and at various times, a 100-l aliquotwas taken out of themixture
and immediately fixed in 1% paraformaldehyde in HT (30 min). The fixed platelets were processed for flow cytometry using FITC-labeled m-Fab as described
under “Experimental Procedures.” C, agonist concentration dependence of dimer increasewasmeasured for CRP at 0.1–2.0g/ml (upper panel) and thrombin
at 0.1–0.5 units/ml (lower panel) using washed platelets (1 108 cells/ml) and FITC-labeled m-Fab-F (100 g/ml, final concentration).
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indicate that bivalent anti-GPVI IgG binds to two copies of the
antigen on the platelet surface (Fig. 7C, panel i). Similar conclu-
sions were drawn for the quantitation of platelet integrin IIb3
(20). Thus, the actual number of single-chain GPVI molecules
on platelets is twice the number calculated from the number of
IgG on the calibration beads. Therefore, the number of mouse
IgG equivalents from the calibration curve (Fig. 7C, panel iv) is
doubled to obtain the actual number of dimers: 6244  558
(204-11 IgG, n 9), 5702 294 (1G5, n 7), and 6034 496
(1G5 Fab, n 4), average of 5993. Fig. 8 shows that resting and
thrombin-activated platelets have similar levels of total GPVI.
InCRP-activated platelets, the totalGPVI determinedwith 1G5
Fab is similar to that observed in resting and thrombin-activated
platelets, although it is lower whenmeasured using 204-11 IgG or
1G5. We do not know the reason for this difference at present. It
should be noted that nomatter which of the three antibodies was
used, no platelet sample showed an increase in total GPVI upon
activation by either CRP or thrombin.
The number of GPVI dimers was calculated from the mea-
sured values by the following method. The binding of dimer-
specific 204-11 Fab to immobilized dimer (Bmax 0.35 0.01
A450 units/well) is about half that of 204-11 IgG (Bmax 0.66
FIGURE 7. Determination of the stoichiometry of antibody binding and method for calculation of the number of GPVI dimers and total GPVI in
platelets. A, binding of 1G5 IgG (gray closed circles) and Fab (black closed triangles) to immobilized dimer was determined by ELISA using HRP-labeled
anti-mouse Fab; these antibodies have the sameBmax.B,bindingof 204-11 IgG (gray closed circles) and 204-11 Fab (black closed triangles) to immobilizeddimer;
the Bmax of 204-11 Fab binding is half that of 204-11 IgG binding. Binding of antibodywas expressed as the absorbance at 450 nm. A and B, data presented are
representativeof twoexperimentsgiving similar and consistent results; eachpoint is themeanS.E. of triplicatedeterminations.Datawere fittedbynonlinear
regression, and the Bmax values were calculated. C, method for calculating the actual number of GPVI dimers and total GPVI, in terms of single chain GPVI
molecules, from quantitation data obtained by flow cytometry using 204-11, 1G5, or 1G5Fab as the primary antibody for determining total GPVI (panel i) and
204-11 Fab as the primary antibody for determining the number of GPVI dimers (panel ii). The secondary antibody was FITC anti-mouse F(ab)2. The binding
reaction for the Biocytex Gp quantitation kit calibration beads containing known amounts ofmouse IgG is shown in panel iii. A calibration curvewas obtained
for each experiment; and a representative one is shown in panel iv. Refer to the text for a full description of the calculation method.
TABLE 4
Flow cytometric quantitation of the number of GPVI dimers in resting
and activated platelets
Platelet preparation n
No. of dimers
per plateleta
% GPVI in
dimer formb
% increase
after activation
Resting platelets 9 861 7.6 29
CRP-activated 8 1174 148 40 37
Thrombin-activated 8 1326 152 44 55
a The number of dimers/platelet was calculated as described under “Results” and
in Fig. 7.
b Percentages calculated with respect to the number of total single chain GPVI
molecules; the average of data obtained using 204-11 IgG, 1G5 Fab, and 1G5
IgG is as follows: 5994 single GPVI molecules/platelet; each dimer two single-
chain GPVI molecules.
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0.01 A450 units/well) (Fig. 7B), so one dimer binds one 204-11
Fab molecule (Fig. 7C, panel ii); because one FITC anti-mouse
F(ab)2 would bind to two anti-GPVI Fabs, each on a different
dimer, thismeans that eachmeasured FITC anti-mouse F(ab)2
is equivalent to two dimers (Fig. 7C, panel ii). Thus the true
number of GPVI dimers is twice the value obtained from the
calibration curve. So the number of mouse IgG equivalents
from the calibration is doubled to obtain the actual number of
dimers: 862 96 (n 9), 1174 148 (n 8), and 1326 152
(n  8) in resting, CRP-activated, and thrombin-activated
platelets (Fig. 8). Therefore the number ofGPVI dimers is 28.6%
of the totalGPVI in the resting platelets, significantly increasing
to 39.2 and 44.2% of the total GPVI in CRP- and thrombin-
activated platelets, respectively.
Inhibition of Static Platelet Adhesion by Anti-GPVI Anti-
bodies—All four anti-GPVI antibodies (at concentrations in
great excess of their Kd value for dimer) significantly inhib-
ited GPVI-dependent static platelet adhesion to fibrous col-
lagen III (i.e. in the presence of EDTA). Inhibition by dimer-
specific m-Fab-F (200 g/ml, 4.2 M) is not significantly
different from that caused by 10B12 (50 g/ml, 1.8 M) or
1C3 (50 g/ml, 1.8 M), which bind both dimer and mono-
mer, suggesting that the dimer is the form primarily respon-
sible for static platelet adhesion to fibrous collagen (Fig. 9).
The milder effect of 204-11 Fab (100 g/ml, 2.1 M) on
GPVI-dependent platelet adhesion is consistent with its par-
tial inhibition of dimer binding to collagen III in ELISA. The
GPVI-dependent component of adhesion is about 34% of the
adhesion due to integrin 21 in the presence of Mg2	,
which is mainly integrin 21-dependent; this is slightly
inhibited by m-Fab-F (p  0.05).
Effect of Anti-GPVI Dimer Antibodies on Platelet Adhesion
under Flow Conditions—At the low shear rate of 300 s1,
m-Fab-F (200 g/ml, 4.2 M) inhibited platelet adhesion to
immobilized collagen (Fig. 10A), with mainly single and
therefore nonactivated platelets adhering to the collagen, in
contrast to the patterns for control human Fab and 204-11
Fab (100 g/ml, 2.1 M), where most adherent platelets were
in aggregates (Fig. 10A); this is reflected in the surface cov-
erage data (Fig. 10B). Inhibition by 10B12 (50 g/ml, 1.8 M)
is similar to that produced by m-Fab-F (data not shown).
These observations are confirmed by the marked decrease in
the average thrombus height and ZV50 (Fig. 10B) in m-Fab-
treated blood, indicating the decrease of thrombus size and
low platelet activation. The decreased surface coverage in
the presence of m-Fab-F can be at least partially explained by
the decrease of activation through the GPVI dimer and thus
of thrombus formation. 204-11 Fab (100 g/ml) did not
inhibit surface coverage and mildly decreased mean throm-
bus height and ZV50.
At 1000 s1, there was high surface coverage and throm-
bus formation in the control sample (mouse Fab or human
Fab, data not shown); surface coverage was slightly inhibited
by 204-11 Fab and decreased about 50% by m-Fab-F (200
g/ml). 204-11 Fab and m-Fab both markedly decreased
mean thrombus height and ZV50, with m-Fab-F being the
more inhibitory (Fig. 10B). Under both shear rates, the anti-
GPVI dimer antibodies inhibited the size of thrombi formed
much more strongly than surface coverage, indicating that
they especially inhibit platelet activation on the collagen sur-
face under flow conditions.
DISCUSSION
What advantage does the presence of GPVI dimers on the
platelet surface offer for collagen recognition, and do dimers
exist in sufficient numbers to be physiologically meaningful for
platelet function? We performed this study to answer these
questions, and our results demonstrate that constitutive
dimerization enables GPVI to recognize and bind with high
affinity to specific sequences in its ligand, collagen. Thus, the
GPVI dimer is the form involved in collagen binding, while the
low affinity monomer is not and instead provides a pool of
dimer components to be called upon when platelets are
activated.
Differential Affinity of GPVI Dimer and Monomer for Colla-
gen Model Peptides—CRP, a triple-helical collagen model
peptide containing 10 consecutive GPO triplets (21), was the
first reagent reported to bind specifically and activate the
platelet collagen receptor GPVI (21, 22). Screening the abil-
ity of model collagen peptides containing various arrange-
ments of GPO triplets to bind recombinant protein consist-
ing of the GPVI extracellular D1 and D2 domains (D1D2)
established that the GPO sequence is a main determinant of
GPVI recognition (12, 13, 17). By docking CRP onto D1D2,
which forms a dimer in the crystal, Horii et al. (7) proposed
the CRP-binding site as a shallow groove defined by charged
residues Lys-41, Lys-59, Arg-60, and Arg-166 on the D1
FIGURE 8.Quantitation of GPVI dimers and total GPVI by flow cytometry.
GPVI dimers are quantitated by using 204-11 Fab as the primary antibody,
and total GPVI is quantitated by 204-11 IgG, 1G5 Fab, or 1G5 IgG (data for all
three primary antibodies shown in the graph); the secondary antibody FITC
anti-mouse F(ab)2 was used for all determinations, including the standard
curvewith themouse IgG-bound beads. Each bar represents themean S.E.
of the indicated number of platelet samples; see Table 4 for a summary of the
quantitation data and “Results” (Quantitation of GPVI Dimers by FlowCytom-
etry) and Fig. 6 for a detailed description of the calculation method. As
observed in the other two methods, compared with the number of GPVI
dimers in resting platelets, both CRP (p  0.0018, n  8) and thrombin
increased the amount of dimer (p  0.0243, n  8). Compared with resting
platelets, thrombin-activated platelets have a similar amount of total GPVI,
although CRP-activated platelets have less. *, p 0.01–0.05.
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domain. Mutational studies show these residues are able to
recognize CRP.
However, the ability ofGPVI to recognize theGPO sequence in
collagen may not completely explain why GPVI dimer displays
such markedly higher affinity, compared with the monomer, for
collagen and its model peptides (Fig. 1 and Table 2). GPVI dimer
binds with similarKd values to all of the substrates, but the severe
rightward shift of the corresponding binding curves of GPVI
monomer indicates its much lower binding affinity. Compared
with the other peptides, monomer binds to CRP and (GPO)2-
(GPP)4(GPO)2with higher affinity, albeitwithmuch lower affinity
than the dimer, suggesting that the closely spaced GPO triplets in
these two peptides may allow monomers to bind close enough
together to interact, thereby reinforcing their affinity; this is con-
sistent with O’Connor et al. (23) who reported higher binding of
D1D2 to peptides containingmore GPO triplets.
FIGURE9.Effectofdimer-specific antibodiesonstaticplateletadhesion to fibrouscollagen.Wemeasured staticplatelet adhesion to fibrous collagen type
III immobilized towells of a 96-well Nunc ImmobilizerTMAminoplate, as describedunder “Experimental Procedures.”Washedplateletswerepreincubatedwith
anti-GPVI antibodies,m-Fab-F (200g/ml, 4.2M), 204-11 Fab (100g/ml, 2.1M), 10B12 (50g/ml, 1.8M), 1C3 (50g/ml, 1.8M), or human Fab as a control
(200 g/ml, 4.2 M) prior to initiating the platelet adhesion assay in the presence of 1 mM MgCl2 (total adhesion) or 5 mM EDTA (GPVI-dependent adhesion).
Adhered platelets were lysed, and alkaline phosphatase in the lysatewas assayed by its hydrolysis of p-nitrophenyl phosphate to p-nitrophenol, detectable by
its absorbance at 405 nm. In the absence of any antibody, platelet adhesion to fibrous collagen in the presence of EDTAwas about 34% that in the presence of
Mg2	. All the anti-GPVI antibodies significantly inhibited GPVI-dependent adhesion. The inhibition exerted by dimer-specific m-Fab-F was not significantly
different from those by 10B12 and 1C3, antibodies that bind to both GPVI monomer and dimer, suggesting that the monomer contributes little to GPVI-de-
pendent adhesion. Dimer-specific 204-11 Fab exerted less inhibition than m-Fab-F, consistent with its epitope being near but discrete from the collagen-
binding site of the dimer. Onlym-Fab-F exerted significant, but slight, inhibition of adhesion in the presence ofMg2	. The control Fab had no effect on platelet
adhesion.
FIGURE 10. Effect of dimer-specific antibodies on the platelet adhesion to a collagen surface under flow conditions. 3,3-Dihexyloxacarbocyanine
iodide-labeledblood in thepresenceof ananti-GPVI-dimer antibody,m-Fab-F (200g/ml, 4.2M)or 204-11 Fab (100g/ml, 2.1M), or control Fab (200g/ml,
4.2M) was flowed over a surface of immobilized collagen (type III) at 300 or 1000 s1 for 5min, and adhered platelets were analyzed. A, fluorescent images of
adhered platelets. m-Fab-F-treated blood (right panel) showed decreased platelet adhesion at both shear rates, showing markedly decreased thrombus
formation relative to the control blood (left panel, human Fab). 204-11 Fab did not decrease platelet adhesion at 300 s1 (top row,middle panel), but decreased
it at 1000 s1. B, surface coverage of adhered platelets was calculated from the images inA; mean thrombus height and ZV50, thrombus height at half-maximal
thrombus height, were plotted from the data obtained at shear rates of 300 and 1000 s1. At either shear rate, both 204-11 Fab and m-Fab-F reduced the %
surface coverage, a measure of adhesion, and mean thrombus height and ZV50, which show the extent of platelet activation. m-Fab-F, which binds to the
collagen-binding site of the dimer, exerts a larger effect than 204-11. The control mouse Fab or human Fab (data not shown) did not affect adhesion or
thrombus formation.
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However, compared with D1D2, dimer binding is less
influenced by a high GPO content, with binding to (GPO)2
and (GPO)2(GPP)4(GPO)2 being similar to that for CRP, sug-
gesting that the GPOGPO sequence, the common motif in
these peptides, is a structure to which dimers can bind with
high affinity. A model peptide with only one GPO (Fig. 2A)
has about 6-fold lower affinity than those containing two or
more GPO triplets, further supporting this idea. It is inter-
esting that the optimal binding of dimeric GPVI is obtained
with peptides containing tandem GPO triplets, with little
further increase in affinity obtained with a further increase
in GPO content, which contrasts with the stepwise increase
in hD1D2 binding reported by Smethurst et al. (19). More
GPO triplets may enable a monomeric D1D2 to interact with
a second molecule of D1D2, increasing its affinity, whereas
dimeric GPVI is already in the conformation with the highest
affinity.
Dimer Binding to Toolkit III Peptides—To determine
whether our findings using model peptides can be extended to
the primary sequence of triple-helical collagen, screening the
collagen Toolkit III peptides for their ability to bind to dimer
yielded one high affinity peptide (III-30), four of intermediate
affinity (III-1, III-4, III-22, and III-40), and three of low affinity
(III-9, III-39, and III-49). The Kd values of dimer binding (inset
of Fig. 3) showed that they all bound dimer with much higher
affinity than monomeric D1D2 (17) or GPVI monomer (data
not shown). No obvious close relationship between the number
of GPO triplets and dimer binding affinity is suggested by the
Kd values, so there may be other determinants of binding.
Dimerization vastly improves the interaction with these pep-
tides, compared with the monomer, suggesting that a unique
binding site is formed when two chains of GPVI form a dimer.
Does the Dimer Bind to One or Across Several Triple-helical
Peptides?—We found that a high density of (GPO)10, a peptide
that exists as single triple-helical molecules, is required to sup-
port dimer binding, with apparent affinity dropping precipi-
tously as the density decreases, strongly suggesting that the
dimer binds to more than one collagen helix. This is further
supported by the fact that precross-linked CRP (CRP-XL) does
not exhibit this drop-off in affinity, with decreasing density only
having a slight effect over a large density range, presumably
because cross-linking forms a polymer in which peptide helices
are held in close enough proximity for the dimer to bind across
several helices. Themodel proposed byHorii et al. (7) describes
the binding site on theGPVImolecule as a shallow groove, large
enough to fit three GPO triplets but not multiple helices. Our
data therefore suggest that both component molecules of the
dimer contribute to binding in a cooperative fashion, forming a
composite binding site able to interact with two or more adja-
cent collagen helices, as might occur in nature, for example
within a collagen fiber, shown schematically in the paper by
Herr and Farndale (24).
Recognition of GPVI by Dimer-specific Antibodies and Those
That Recognize Both Forms—The epitopes of the anti-GPVI
antibodies were examined by determining their dimer and
monomer binding specificities (Fig. 4 and Table 3) and their
effect on dimer binding to collagenous substrates (Fig. 5).
m-Fab-F and 204-11 Fab were dimer-specific. 204-11 IgG, 1G5,
and 1C3 bound both dimer and monomer; notably, 1G5
showed higher affinity for the monomer than the dimer. 1C3,
whose epitope may be near the dimer interface (23), may pre-
vent dimer formation. Dimer-specific m-Fab-F and 204-11 Fab
showed different patterns of inhibition against dimer binding.
m-Fab-Fmarkedly inhibited the binding to all collagenous sub-
strates, except for binding to CRP, which was decreased about
30% by this Fab, suggesting that its epitope may lie near the
collagen recognition site of the dimer (Fig. 5). m-Fab-F recog-
nizes a structure specific for the dimer conformation, previ-
ously suggested to be involved in GPVI binding to collagen (8).
Interestingly, Val-34 and Leu-36 present at the distal end of D1
were reported to contribute to collagen binding (25), suggesting
that a site other than that binding GPO triplets may also inter-
act with collagen. m-Fab-F may also recognize such a site,
which is different from the positive groove suggested as a GPO-
binding site in the model of Horii et al. (7). The partial inhibi-
tion of dimer binding produced by 204-11 Fab against all col-
lagenous substrates other than CRP suggests that it binds to a
specific site discrete from the collagen-binding site, yet close
enough to hinder ligand binding. 204-11 IgG was observed to
increase the binding of m-Fab-F to dimer (8), so it may also
influence the conformation of the dimer.
Constitutive GPVI Dimers in Resting Platelets and Increase in
Dimer Density upon Platelet Activation—Flow cytometric
measurement of the relative amounts of GPVI dimer using
FITC-labeled m-Fab-F indicated that resting platelets contain
substantial amounts of GPVI dimer, which increased signifi-
cantly after activation by either CRP or thrombin in concentra-
tion- and time-dependent manner. Quantitation of dimer
number using the 204-11 Fab/FITC anti-mouse antibody sys-
tem showed that 29% of the total GPVI in resting platelets is
dimeric, increasing to 39 and 44% in CRP- and thrombin-acti-
vated platelets, respectively.
Our results contrast with the recent report by Loyau et al.
(26) that few resting platelets were positive for dimer (2.25%)
and that thrombin receptor-activating peptide activation
increased the percent of dimer-positive platelets. It is difficult
to compare their results with ours because they reported the
percentage of platelets positive for antibody binding, whereas
we quantitated the number of dimers per platelet; and they used
a different anti-GPVI-dimer antibody, 9E18, which may recog-
nize a different epitope in the dimer or a different form of GPVI
dimer.
GPVI Dimeric Homeostasis—Themechanisms that maintain
some GPVI in the dimeric state in quiescent platelets remain
to be established. We discount the possibility that two GPVI
molecules are complexed with one FcR to form a GPVI
dimer, because an increase of dimer levels upon activation
would entail the addition of a free GPVI molecule to a GPVI-
FcR- complex, yet no free GPVI has been detected in
human platelets. Instead, GPVI dimer would be formed from
two GPVI monomers, each complexed with a homodimeric
FcR, supporting the hypothesis of Berlanga et al. (9) and
Feng et al. (27). Although the dimer was suggested to be
formed from two D1D2, their weak affinity for each other
makes spontaneous dimer formation in resting platelets
unlikely under physiological conditions. Whether collagen
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binding stabilizes the dimeric form, as suggested by rapid
dimerization of GPVI chains linked near the C terminus,
cytoplasmic domains upon platelet activation (28) remain to
be determined. Furthermore, because dimer formation is
increased by both CRP and thrombin, it is tempting to sug-
gest that there are other yet-unidentified signaling pathways
to facilitate formation of more dimers or multimers of
dimers, thereby reinforcing activation.
Physiological Role of GPVI Dimers—The physiological func-
tion of GPVI dimer was addressed by analyzing the effects of
anti-GPVI antibodies on platelet activation by collagen. Jung
et al. (8) showed that m-Fab-F inhibits collagen-induced
platelet aggregation and GPVI dimer binding to collagen
fibers. Here, we show that m-Fab-F inhibits adhesion of
platelets to collagen under both static and flow conditions.
About 34% of static platelet adhesion to collagen is through
GPVI, with the remaining adhesion mainly due to the other
platelet collagen receptor integrin 21. m-Fab-F markedly
inhibits the GPVI-dependent component of adhesion to a
level similar to that achieved with either 10B12 or 1C3 that
binds both forms of GPVI, suggesting that monomeric GPVI
contributes little to this adhesion. The flow adhesion exper-
iment employed conditions similar to those of the vascular
system in vivo, low shear (300 s1) occurring in large arteries
and high shear (1000 s1) in medium-sized arteries (29), and
it showed that m-Fab-F specifically inhibited thrombus for-
mation on collagen. Previous flow studies have demon-
strated defective thrombus formation on immobilized colla-
gen using blood from GPVI-deficient patients (30, 31) and
blood treated with an anti-GPVI antibody also showed a sim-
ilar defect (32). In our flow experiments, m-Fab-F-treated
blood showed defective thrombus formation to an extent
similar to that seen in GPVI-deficient platelets, suggesting
that GPVI dimer is the form contributing to thrombus for-
mation under physiological conditions. Treatment with
m-Fab-F markedly decreased the mean thrombus height and
ZV50, parameters reporting platelet activation (18), consist-
ent with the dimer being the form of GPVI that binds to
collagen to initiate signaling pathways leading to platelet
activation. 204-11 Fab decreased GPVI-dependent static
adhesion and decreased both mean thrombus height and
ZV50 under flow to a lesser extent than m-Fab-F, consistent
with its epitope being dimer-specific but discrete from the
collagen-binding site.
Conclusions and Implications of GPVI Dimerization—We
have demonstrated that there is constitutive dimerization of
GPVI in quiescent platelets; GPVI dimers exist in sufficient
numbers to be the form of GPVI that contributes to platelet
adhesion to collagen and is the form through which platelet
activation is initiated upon collagen engagement. The pre-exis-
tence of high affinity GPVI dimers provides a mechanism for
early engagement of GPVI, essential given the transient
encounter of platelets with blood vessel collagens after arterial
damage, and it is consistent with the prominence of GPVI in
animal and in vitromodels of thrombus deposition under flow.
Moreover, the ability of thrombin, and perhaps other stimuli, to
up-regulate GPVI dimer expression on the platelet surface
offers a mechanism for sensitizing the circulating platelet to
exposed subendothelial collagens.
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